Børn og unge (2- 18 år) Den systemiske eksponering for hydroxycarbamid er for børn og unge den samme som for voksne patienter.
Children and adolescents (2-18 years old) In children and adolescents with Sickle Cell Syndrome, systemic exposure to hydroxycarbamide is similar to adult patients.